GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BetterLife Pharma Inc (XCNQ:BETR) » Definitions » Cyclically Adjusted Book per Share

BetterLife Pharma (XCNQ:BETR) Cyclically Adjusted Book per Share : C$0.04 (As of Apr. 2024)


View and export this data going back to 2017. Start your Free Trial

What is BetterLife Pharma Cyclically Adjusted Book per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

BetterLife Pharma's adjusted book value per share for the three months ended in Apr. 2024 was C$-0.093. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is C$0.04 for the trailing ten years ended in Apr. 2024.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Book Growth Rate of BetterLife Pharma was 42.80% per year. The lowest was 29.40% per year. And the median was 36.10% per year.

As of today (2024-09-21), BetterLife Pharma's current stock price is C$0.13. BetterLife Pharma's Cyclically Adjusted Book per Share for the quarter that ended in Apr. 2024 was C$0.04. BetterLife Pharma's Cyclically Adjusted PB Ratio of today is 3.25.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of BetterLife Pharma was 5.85. The lowest was 0.00. And the median was 0.00.


BetterLife Pharma Cyclically Adjusted Book per Share Historical Data

The historical data trend for BetterLife Pharma's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BetterLife Pharma Cyclically Adjusted Book per Share Chart

BetterLife Pharma Annual Data
Trend Jan15 Jan16 Jan17 Jan18 Jan19 Jan20 Jan21 Jan22 Jan23 Jan24
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.80 -0.54 -0.32 -0.15 0.02

BetterLife Pharma Quarterly Data
Jul19 Oct19 Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.09 -0.03 - 0.02 0.04

Competitive Comparison of BetterLife Pharma's Cyclically Adjusted Book per Share

For the Biotechnology subindustry, BetterLife Pharma's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BetterLife Pharma's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BetterLife Pharma's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where BetterLife Pharma's Cyclically Adjusted PB Ratio falls into.



BetterLife Pharma Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, BetterLife Pharma's adjusted Book Value per Share data for the three months ended in Apr. 2024 was:

Adj_Book= Book Value per Share /CPI of Apr. 2024 (Change)*Current CPI (Apr. 2024)
=-0.093/126.8896*126.8896
=-0.093

Current CPI (Apr. 2024) = 126.8896.

BetterLife Pharma Quarterly Data

Book Value per Share CPI Adj_Book
201407 -0.521 99.315 -0.666
201410 -0.666 99.473 -0.850
201501 -0.010 98.209 -0.013
201504 -0.008 99.710 -0.010
201507 0.023 100.579 0.029
201510 0.009 100.500 0.011
201601 -0.062 100.184 -0.079
201604 -0.085 101.370 -0.106
201607 -0.122 101.844 -0.152
201610 -0.206 102.002 -0.256
201701 -0.255 102.318 -0.316
201704 -0.313 103.029 -0.385
201707 -0.211 103.029 -0.260
201710 0.030 103.424 0.037
201801 -0.007 104.056 -0.009
201804 0.670 105.320 0.807
201807 0.486 106.110 0.581
201810 0.469 105.952 0.562
201901 0.361 105.557 0.434
201904 0.318 107.453 0.376
201907 0.968 108.243 1.135
201910 0.851 107.927 1.001
202001 0.154 108.085 0.181
202004 0.173 107.216 0.205
202007 0.130 108.401 0.152
202010 0.064 108.638 0.075
202101 -0.090 109.192 -0.105
202104 -0.064 110.851 -0.073
202107 0.015 112.431 0.017
202110 -0.009 113.695 -0.010
202201 -0.046 114.801 -0.051
202204 -0.076 118.357 -0.081
202207 -0.086 120.964 -0.090
202210 -0.115 121.517 -0.120
202301 -0.119 121.596 -0.124
202304 -0.083 123.571 -0.085
202307 -0.086 124.914 -0.087
202310 -0.081 125.310 -0.082
202401 -0.093 125.072 -0.094
202404 -0.093 126.890 -0.093

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.


BetterLife Pharma  (XCNQ:BETR) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

BetterLife Pharma's Cyclically Adjusted PB Ratio of today is calculated as

Cyclically Adjusted PB Ratio=Share Price/Cyclically Adjusted Book per Share
=0.13/0.04
=3.25

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of BetterLife Pharma was 5.85. The lowest was 0.00. And the median was 0.00.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


BetterLife Pharma Cyclically Adjusted Book per Share Related Terms

Thank you for viewing the detailed overview of BetterLife Pharma's Cyclically Adjusted Book per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


BetterLife Pharma Business Description

Industry
Traded in Other Exchanges
Address
1275 West 6th Avenue, Suite 300, Vancouver, BC, CAN, V6H 1A6
BetterLife Pharma Inc a biotechnology company, engages in the development and commercialization of psychedelic products for the treatment of mental disorders in Canada, the United States, Australia, and European Union. It is involved in refining and developing drug candidates from a set of complementary interferon-based technologies that have the potential to engage the immune system to fight virus infections, such as coronavirus disease and human papillomavirus, and/or to directly inhibit tumors to treat various types of cancer.
Executives
Ahmad Doroudian Director, Senior Officer